<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00985426</url>
  </required_header>
  <id_info>
    <org_study_id>DV2-HBV-17</org_study_id>
    <secondary_id>2009-015877-11</secondary_id>
    <nct_id>NCT00985426</nct_id>
  </id_info>
  <brief_title>Immunogenicity and Safety of HEPLISAV™ Hepatitis B Virus Vaccine in Chronic Kidney Disease (CKD) Patients</brief_title>
  <official_title>An Observer-Blinded, Randomized Study Comparing the Safety and Immunogenicity of HEPLISAV™ to Licensed Vaccine (Engerix-B®) Among Adults(18 to 75 Years of Age) With Chronic Kidney Disease (CKD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dynavax Technologies Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Dynavax Technologies Corporation</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to explore the safety and immunogenicity of a new investigational
      hepatitis B virus vaccine, HEPLISAV™, in patients 18 to 75 years of age who have progressive
      loss of kidney function.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of the study is to explore the safety and Immunogenicity of a new investigational
      hepatitis B virus vaccine, HEPLISAV™, in patients 18 to 75 years of age who have progressive
      loss of kidney function.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2009</start_date>
  <completion_date type="Actual">January 2012</completion_date>
  <primary_completion_date type="Actual">January 2012</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of subjects who have a seroprotective immune response (anti-HBsAg antibody≥ 10 milli-international unit (mlU)/mL) at week 28.</measure>
    <time_frame>week 28</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall incident of post-injection reactions and adverse events in each treatment group</measure>
    <time_frame>week 52</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">521</enrollment>
  <condition>Chronic Kidney Disease</condition>
  <arm_group>
    <arm_group_label>HEPLISAV and Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>0.5 mL HEPLISAV and Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Engerix-B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>2.0 mL Engerix-B</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>HEPLISAV and Placebo</intervention_name>
    <description>Intramuscular (IM) injections of HEPLISAV at Weeks 0, 4, and 24; placebo(saline) injection at Week 8</description>
    <arm_group_label>HEPLISAV and Placebo</arm_group_label>
    <other_name>Hepatitis B vaccine (recombinant), adjuvanted</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Engerix-B</intervention_name>
    <description>Intramuscular (IM) injections at Weeks 0, 4, 8, and 24</description>
    <arm_group_label>Engerix-B</arm_group_label>
    <other_name>Hepatitis B vaccine (recombinant)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  be 18 to 75 years of age;

          -  progressive loss of renal function as defined by glomerular filtration rate (GFR) ≤ 45
             mL/min/1.73 m²;

          -  be clinically stable in the opinion of the investigator;

          -  be serum negative for HBsAg, anti-HBsAg, antibody to hepatitis B core antigen (HBcAg),
             Hepatitis C virus (HCV), and human immunodeficiency virus (HIV);

          -  if a woman of childbearing potential, agree to consistently use a highly effective
             method of birth control from screening visit through the treatment phase and for up to
             28 days after the last injection;

          -  is not scheduled to undergo a kidney transplant in the next 12 months;

          -  be able and willing to provide informed consent.

        Exclusion Criteria:

          -  if female, is pregnant, breastfeeding, or planning a pregnancy;

          -  has a history of or is considered by the investigator to be at high risk for recent
             exposure to HBV, HCV, or HIV; for example, current intravenous drug use, has
             unprotected sex with known HBV/HIV positive partner;

          -  has known history of autoimmune disease;

          -  has previously received any HBV vaccine;

          -  has a history of sensitivity to any component of study vaccines;

          -  has current illness other than renal disease or has substance or alcohol abuse that in
             the opinion of the investigator would interfere with compliance or with interpretation
             of the study results;

          -  is undergoing chemotherapy or expected to receive chemotherapy during the study
             period; has a diagnosis of cancer within the last 5 years other than squamous or basal
             cell carcinoma of the skin;

          -  has uncontrolled diabetes or hypertension;

          -  is unwilling or unable to comply with all the requirements of the protocol;

          -  has received any blood products or immunoglobulin within 3 months prior to study
             entry, or likely to require infusion of blood products during the study period;

          -  has received the following prior to the first injection:

          -  3 days: erythropoietin (exclusionary window does not apply for subjects on dialysis)

          -  7 days: intravenous iron

          -  21 days: any inactivated virus vaccine

          -  28 days:

          -  any live virus vaccine

          -  systemic corticosteroids (more than 3 consecutive days) or other immunomodulators or
             immune suppressive medication, with the exception of inhaled steroids

          -  granulocyte or granulocyte-macrophage colony-simulating factor (G/GM-CSF), any other
             investigational medicinal agent

          -  At any time: an injection of deoxyribonucleic acid plasmids or oligonucleotide
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert Janssen, MD</last_name>
    <role>Study Director</role>
    <affiliation>Dynavax Technologies Corporation</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Clinical Research Associates of Tidewater</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23507</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.dynavax.com/</url>
  </link>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 24, 2009</study_first_submitted>
  <study_first_submitted_qc>September 25, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 28, 2009</study_first_posted>
  <disposition_first_submitted>June 16, 2014</disposition_first_submitted>
  <disposition_first_submitted_qc>June 16, 2014</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">June 19, 2014</disposition_first_posted>
  <last_update_submitted>February 20, 2018</last_update_submitted>
  <last_update_submitted_qc>February 20, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 22, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>chronic kidney disease</keyword>
  <keyword>kidney failure</keyword>
  <keyword>kidney failure,chronic</keyword>
  <keyword>chronic kidney failure</keyword>
  <keyword>hepatitis B virus (HBV) vaccine</keyword>
  <keyword>hepatitis B vaccine</keyword>
  <keyword>hepatitis B</keyword>
  <keyword>hepatitis</keyword>
  <keyword>HBV</keyword>
  <keyword>prevention and control</keyword>
  <keyword>dialysis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Hepatitis B</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

